Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival

Cancer Cell International

Volumn 5, Issue , 2005, Pages

  Yang, Qing ^a   Fung, Kar Ming ^a,b   Day, Wanda V ^a   Kropp, Bradley P ^a   Lin, Hsueh Kung ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; Prostate cancer; RNA interference

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ENHANCED GREEN FLUORESCENT PROTEIN; HISTONE H2B; MESSENGER RNA; SMALL INTERFERING RNA;

5' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; EXPRESSION VECTOR; GENE REPRESSION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MALE; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 18144365852     PISSN: 14752867     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2867-5-8     Document Type: Article

References (45)

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004, 25:276-308.
2. Roche PJ, Hoare SA, Parker MG. A consensus DNA-binding site for the androgen receptor. Mol Endocrinol 1992, 6:2229-2235.
3. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002, 99: 11890-11895.
4. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993, 7:1541-1550.
5. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 2001, 15:46-56.
6. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O-P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genetics 1995, 9:401-406.
7. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996, 271:19900-19907.
8. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002, 277:38087-38094.
9. Stoner E. The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990, 37:375-378.
10. Soloway MS, Matzkin H. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 1993, 71:1083-1088.
11. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urol 1995, 46:142-148.
12. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000, 7:997-1007.
13. Chen S, Song CS, Lavrovsky Y, Bi B, Vellanoweth R, Chatterjee B, Roy AK. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol 1998, 12:1558-1566.
14. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002, 62:1008-1013.
15. Cogoni C, Macino G. Post-transcriptional gene silencing across kingdoms. Curr Opin Genet Dev 2000, 10:638-643.
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
17. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101:25-33.
18. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003, 17:1726-1737.
19. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002, 26:199-213.
20. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci, USA 1992, 89:6319-6323.
21. Brinkmann AO, Jenster G, Ris-Stalpers C, van der Korput JAGM, Brüggenwirth HT, Boehmer ALM, Trapman J. Androgen receptor mutations. J Steroid Biochem Mol Biol 1995, 53:443-448.
22. Barrack ER. Androgen receptor mutations in prostate cancer. The Mount Sinai J of Med 1996, 63:403-412.
23. Gou D, Jin N, Liu L. Gene silencing in mammalian cells by PCR-based short hairpin RNA. FEBS Letters 2003, 548:113-118.
24. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol 2004, 172:1140-1144.
25. Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004, 23:3350-3360.
26. Ajiro K. Histone H2B phosphorylation in mammalian apoptotic cells. An association with DNA fragmentation. J Biol Chem 2000, 275:439-443.
27. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, Beeser A, Etkin LD, Chernoff J, Earnshaw WC, Allis CD. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 2003, 113:507-517.
28. Lee EC, Zhan P, Schallhom R, Packman K, Tenniswood M. Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Diff 2003, 10:761-771.
29. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999, 59:2891-2897.
30. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003, 63: 49-153.
31. Godoy-Tundidor S, Hobisch A, Pfeil K, Bartsch G, Culig Z. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 2002, 8:2356-2361.
32. Zhan P, Lee EC, Packman K, Tenniswood M. Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells. J Steroid Biochem Mol Biol 2002, 83:101-111.
33. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999, 69:307-313.
34. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59: 2511-2515.
35. Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 1999, 54:1120-1125.
36. Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR, Blackburn EH. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 2004, 64: 833-4840.
37. Park WS, Hayafune M, Miyano-Kurosaki N, Takaku H. Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells. Gene Ther 2003, 10:2046-2050.
38. Iguchi K, Otsuka T, Usui S, Ishii K, Onishi T, Sugimura Y, Hirano K. Zinc and metallothionein levels and expression of zinc transporters in androgen-independent subline of LNCaP cells. J Androl 2004, 25:154-161.
39. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003, 63:2306-2311.
40. Hobisch A, Hoffmann J, Lambrinidis L, Eder IE, Bartsch G, Klocker H, Culig Z. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urol Int 2000, 65:73-79.
41. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33-39.
42. Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002, 20:497-500.
43. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002, 20: 500-505.
44. Nunlist EH, Dozmorov I, Tang Y, Cowan R, Centola M, Lin H-K. Partitioning of 5α-dihydrotestosterone and 5α-androstane-3* 17β-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation. J Steroid Biochem Mol Biol 2004, 91:157-170.
45. Kerr JFR, Harmon BV. Definition and incidence of apoptosis: an historical perspective. In Apoptosis. The Molecular Basis of Cell Death. Edited by Tomei LD, Cope FO. Plainview, NY: Cold Spring Harbor Laboratory Press; 1991:5-29.